<table border="1" cellpadding="3" width="85%" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td>
<content stylecode="bold">Coadministered drug</content>
</td>
<td>
<content stylecode="bold">Dose schedules </content>
</td>
<td></td>
<td>
<content stylecode="bold">Effect on other drugs pharmacokinetics</content>
</td>
</tr>
<tr>
<td></td>
<td>
<content stylecode="bold">Coadministered drug</content>
</td>
<td>
<content stylecode="bold">Quetiapine</content>
</td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>2 mg, single dose</td>
<td>250 mg three times daily</td>
<td>Oral clearance of lorazepam reduced by 20%</td>
</tr>
<tr>
<td>Divalproex </td>
<td>500 mg twice daily </td>
<td>150 mg twice daily </td>
<td>C<sub>max</sub> and AUC of free valproic acid at steady-state was decreased by 10 to 12% </td>
</tr>
<tr>
<td>Lithium</td>
<td>Â Up to 2400 mg/day given in twice daily doses </td>
<td>250 mg three times daily </td>
<td>No effect on steady-state pharmacokinetics of lithium</td>
</tr>
<tr>
<td>Antipyrine </td>
<td>1 g, single dose </td>
<td>250 mg three times daily </td>
<td>No effect on clearance of antipyrine or urinary recovery of its metabolites </td>
</tr>
</tbody>
</table>